Background: We are currently undertaking a multi-institutional prospective trial of the superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy for patients with T4aN0M0 or T4bN0M0 locally advanced maxillary sinus squamous cell carcinomas (SCC). We herein report the results of the dosefinding phase.
and Development Fund (23-A-16, 23-A-21, 26-A-4) of Japan. The Japan Clinical Oncology Group Data Center collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all of the data in the study and financial responsibility for the decision to submit for publication.
Results: All 18 patients received a full dose of radiotherapy. The number of cycles of cisplatin was 7 in 13 patients and 6 in 5 patients. The dose-limiting toxicities were observed in 5 patients.
Conclusion:
These results indicated that this therapy is safe and well-tolerated at 7 cycles of cisplatin, which was determined to be the recommended number of cycles for locally advanced maxillary sinus SCC.
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| I NT ROD UCTI ON
Locally advanced and resectable maxillary sinus cancers (T3-4a) require radical surgery with or without a complete resection of the orbital contents as a standard treatment. This often results in significant disfigurement and impairment of function in patients with T4a tumors, but this is seldom the case in those with T3 tumors. 1 A significant number of patients with T4a tumors refuse radical surgery because of the fear of disfigurement and functional impairment. Therefore, the development of a new less invasive therapy that is as effective as radical surgery is critical. Concurrent intravenous chemoradiotherapy (i.v.-CRT) is a promising treatment option for locally advanced laryngeal and pharyngeal squamous cell carcinoma (SCC). However, i.v.-CRT does not necessarily lead to satisfactory treatment outcomes in cases of maxillary sinus cancer. 2, 3 In addition, induction chemotherapy has not shown particularly promising results in cases of maxillary sinus cancer either. 4, 5 On the other hand, radical surgery is not indicated for unresectable, locally advanced tumors (T4b), and i.v.-CRT is regarded as a community standard treatment in daily practice. However, the 3-year overall survival for 7 patients with T4bN0M0 in our retrospective study was 14.3%. 6 This indicates that more effective therapies are necessary for patients with T4a who refuse surgery as well as for those with T4b. Intra-arterial chemotherapy has been used to treat localized malignant neoplasms in patients with head and neck cancer for over 50 years based on the fact that the head and neck region is particularly well suited to regional chemotherapy as the blood supply to these tumors is primarily derived from branches of the external carotid artery. Intra-arterial chemotherapy was introduced in the 1960s through the early 1980s in Japan, mainly for the treatment of maxillary sinus cancer, as maxillary sinus cancer accounted for approximately 30% of the cancers arising in the upper aerodigestive tract at that time. However, retrograde intra-arterial infusion via the superficial temporal artery, which was the standard method for intra-arterial chemotherapy at that time, resulted in inadequate selectivity in some patients in whom the cancer was supplied by multiple arteries. Therefore, the drug was not delivered to the cancer adequately in such patients. As a result, some patients seemed to show excellent outcomes while others did not. In reality, the 5-year overall survival was 60%-80% in patients with T3 maxillary sinus cancer that is usually supplied by one artery, whereas it was around 40% in those with T4 cancer that is usually fed by more than one artery. 7, 8 Thereafter, advances in vascular interventional radiology techniques in the 1980s enabled superselective intraarterial infusion to the head and neck structures. "Superselective" has been defined as the procedure in which a catheter is inserted into a branch of the external carotid artery. 9 Robbins et al 10 developed a specific concomitant chemotherapy protocol for head and neck cancer that used the pharmacologic principles of intra-arterial cisplatin while capitalizing on the cisplatin-neutralizing activity of sodium thiosulfate. The intra-arterial infusion procedure involves the angiographic introduction of a transfemoral microcatheter to the branch of the external carotid artery supplying the tumor. Cisplatin is then infused through the microcatheter to the dominant blood supply of the targeted tumor. At the same time, sodium thiosulfate is infused intravenously to neutralize the cisplatin. A phase I study demonstrated that cisplatin could be safely administered to patients with advanced and recurrent head and neck cancer at a dose intensity of 150 mg/m 2 per week.
As the next step, concomitant radiotherapy was added to the high-dose cisplatin infusion strategy. 11 The regimen, referred to as radiation and intra-arterial cisplatin (RADPLAT), was mainly indicated for patients with locally advanced head and neck cancers other than sinonasal cancer in Western countries. However, RADPLAT has also been used for patients with locally advanced sinonasal cancer in several institutions in Japan because the long-term use of the intra-arterial infusion procedure for sinonasal cancer made it readily accepted by physicians. Its use has been reported to result in favorable survival rates. [12] [13] [14] This procedure was introduced in Japan with a reduced dose of 100 mg/m 2 
| M ATE RI ALS AN D ME THO DS

| Patients
For inclusion in this study, patients had to fulfill the following criteria: primary lesion located at the maxillary sinus; histologically proven SCC; clinical stage T4aN0M0 or T4bN0M0; no severe carotid stenosis as evaluated by ultrasonography; aged between 20 and 75 years; Eastern Cooperative Oncology Group performance status of 0 or 1; no prior therapy for maxillary sinus cancer; no prior radiotherapy to the head and neck or the brain; no prior chemotherapy for any other malignancies; sufficient organ function as shown by a peripheral blood white blood cell count of at least 4000 cells per lL and 12,000 cells per lL or less; hemoglobin concentration of at least 9.5 g/dL; platelet count of at least 100 000 cells per lL; serum total bilirubin concentration of 2.0 mg/dL or less; aspartate aminotransferase of 100 IU/L or less; alanine aminotransferase of 100 IU/L or less; serum creatinine concentration of 1.2 mg/dL or less; normal electrocardiogram; the ability to reach the external carotid arteries from the femoral artery with a catheter; and satisfy the normal tissue radiation dose constraints for the ipsilateral eyeball and optic nerve, spinal cord, brainstem, and chiasma. Written informed consent was obtained from all patients before registration.
Patients were excluded if they had any of the following conditions: simultaneous or metachronous (within 5 years) double cancers other than in situ carcinoma or intramucosal tumors; active infection requiring systemic therapy; body temperature 38 8C; women during pregnancy, breastfeeding, or within 28 days after delivery; severe psychosis; need for systemic steroid medication or immunosuppressant medication; poorly controlled diabetes mellitus; poorly controlled hypertension; an angina pectoris attack within 3 weeks or myocardial infarction within 6 months; or were positive for serum hepatitis B antigen.
| Treatment methods
The protocol treatment consisted of weekly superselective intra-arterial infusion of cisplatin with concomitant radiotherapy and salvage surgery where necessary.
| Chemotherapy
In the dose-finding phase, 100 mg/m 2 of cisplatin was administered intra-arterially weekly for 7 weeks. At the same time, sodium thiosulfate was administered at a dose of 20 g/m 2 intravenously to neutralize the cisplatin. Digital subtraction angiography and/or an IVR-CT system, which combines angiography and CT imaging with the patient remaining on the same table, was performed to accurately and carefully identify the arteries feeding the tumor and their perfusion. Tumors of the maxillary sinuses are usually fed by the internal maxillary artery, but for cases in which the facial artery, transverse facial artery, or so on fed the tumor, part of the dose was administered through these alternative arteries. 12, 15 The dose of cisplatin infused from each artery was determined as described in previous reports. The recommended number of cycles was determined in the dosefinding phase for application in the efficacy confirmation phase.
| Radiotherapy
Radiotherapy was administered with high-energy photons by 4 to 10 MV X-rays to a total dose of 70 Gy in 35 fractions 5 times weekly. The gross tumor volume included the volume of the primary tumor. The clinical target volume (CTV) included the gross tumor volume with a 0.5 cm margin and the entire ipsilateral maxillary sinus, at least. The CTV did not include the area of potential lymph node metastasis in the neck. The planning target volume for the CTV was defined as a 0.5 cm margin around the CTV to compensate for setup variations and internal organ motion. To protect normal vital structures, such as the contralateral eye ball and/ or optic nerve, chiasma, spinal cord, and brain, a partial reduction in the planning target volume margin of 0.1 cm from the initial 0.5 cm was allowed.
| Dose-finding method
In the dose-finding phase, 100 mg/m 2 of cisplatin was administered weekly for 7 weeks with concomitant radiotherapy to 18 patients. The dose of cisplatin was not modified in the case of adverse events. The grade of toxicity was assessed according to the Common Terminology Criteria for Adverse Events version 4.0. Cisplatin was skipped in the case of adverse events that met the skipping criteria defined in the protocol as follows: (1) leukopenia grade 3; (2) neutropenia grade 3; (3) thrombocytopenia grade 2; (4) aspartate aminotransferase/alanine aminotransferase grade 2; (5) total bilirubin 2.5 mg/dL; (6) estimated creatinine clearance (CCr) < 50 mL/min; (7) infection grade 3; (8) febrile neutropenia grade 3; (9) body temperature 38 8C with infection; or (10) the need for granulocyte colony-stimulating factor administered on the same day. The recommended number of cycles was determined according to the distribution of the number of cycles of administered cisplatin and the incidence of dose-limiting toxicities. The recommended number of cycles was taken as the maximum number of cycles of administered cisplatin at which no more than one-third of the patients experienced dose-limiting toxicities. More specifically, the mode, the most frequent value, was considered to be the prime candidate for the recommended number of cycles, and the incidence of dose-limiting toxicities among patients who were administered the mode number of cisplatin cycles and that among those administered no more than the mode were compared. If the mode was tolerable, the mode 11 cycle was evaluated in the same way. However, if the mode was not tolerable, the mode -1 cycle was evaluated. Where necessary, mode -2, mode -3, mode 1 2, and mode 1 3 were also evaluated. Continuation of the dose-finding phase with dose escalation to 120 mg/m 2 of cisplatin per cycle was set for consideration in which 12 or more of the 18 patients (twothirds of the patients) were administered 7 cycles of 100 mg/ m 2 of cisplatin.
| Definition of dose-limiting toxicities
The dose-limiting toxicities observation period was defined as the period from the date of the beginning of treatment to 28 days after the last radiotherapy session. Dose-limiting toxicities were defined using the following criteria: (1) grade 3 febrile neutropenia; (2) grade 4 thrombocytopenia; (3) estimated CCr < 40 mL/min; (4) grade 3 or more severe nonhematologic toxicity, except for mucositis, dermatitis, electrolyte abnormalities, and complications related to intervention; (5) radiation break of > 14 days due to toxicity; (6) skipping chemotherapy administration for 3 or more consecutive cycles; and (7) treatment-related death.
| Follow-up
All the patients who were enrolled in the study were to be followed for at least 5 years, while analysis of the primary endpoint of the efficacy confirmation phase was planned to be conducted 3 years after accrual completion. Efficacy and safety were to be evaluated at least every 3 months during the first year, at least every 4 months during the second year, and then every 6 months during the third to fifth years.
| Quality control of intra-arterial chemotherapy
All participating interventional radiologists had to agree to the technical details for superselective intra-arterial chemotherapy prespecified in the study protocol. To control the quality of the interventional technique, the central review of photographs and movies for arbitrarily selected patients was performed at semiannual investigators' meetings. All interventional procedures were performed or directly supervised by interventional radiologists certified by the study chair. The major criteria for certification in this study included: (1) having experienced interventional radiology on 40 occasions with 10 occasions as the principal operator; (2) having experience with 2 patients or more requiring intervention with superselective arterial infusion of cisplatin for head and neck cancer within 2 years; and (3) being board certified in societies related to interventional radiology.
| Study design and statistical analysis
This was a multi-institutional, single-arm, prospective trial of superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy for patients with T4aN0M0 or T4bN0M0 locally advanced maxillary sinus SCCs (see Figure 1) . The trial consisted of a dose-finding phase and an efficacy confirmation phase. The dose-finding phase was designed to determine the recommended number of cycles through the study of patients with either T4aN0M0 or T4bN0M0 tumors. The efficacy confirmation phase is being conducted separately for patients with T4aN0M0 and T4bN0M0 disease. The primary endpoint of the dose-finding phase was the incidence of dose-limiting toxicities. The secondary endpoint was the incidence of adverse events. Toxicities were analyzed at the end of the dose-limiting toxicities observation period for the last patient in the dose-finding phase, and the recommended number of cycles was determined. Based on our previous experience, all patients were expected to be able to tolerate 100 mg/m 2 of cisplatin administration at least 5 times. The planned sample size in the dose-finding phase was 18 patients in order to maintain almost the same precision for the mode number of cycles in a traditional 3 1 3 design when the actual number of cycles ranged from 5 to 7 times for the enrolled patients. Patient demographics and clinical characteristics were summarized using descriptive statistics. For categorical variables, such as patient sex, disease stage, response, and toxicity at each grade level, frequency, and percentage were determined. For numerical variables, such as age and dose of cisplatin administered, the median and range were calculated. All statistical analyses were carried out using SAS software version 9.2 (SAS Institute, Cary, NC). This report is based on the data available as of May 24, 2016. The Protocol Review Committee of the Japan Clinical Oncology Group and the institutional review boards of the participating institutions approved the study protocol. This trial is registered at the UMIN Clinical Trials Registry under trial number UMIN000013706 (http://www.umin.ac.jp/ctr/).
| R ES ULT S
Eighteen patients from 7 institutions were registered in the dose-finding phase between April 2014 and September 2015. Of the 18 patients (14 men and 4 women), 16 were diagnosed as T4aN0M0 and 2 as T4bN0M0. Ages ranged from 40 to 75 years (median 64 years). Other characteristics are shown in Table 1 .
All patients achieved a full dose of radiotherapy. The number of cycles of cisplatin administered was 7 in 13 patients and 6 in 5 patients. The dose-limiting toxicities were observed in 5 patients, with grade 3 liver dysfunction in 1 patient, grade 4 thrombocytopenia in 1 patient, estimated CCr < 40 mL/min in 1 patient, grade 3 retinopathy in 1 patient, and grade 3 retinal detachment in 1 patient were also observed ( Table 2) . Acute toxicities are shown in Table 3 . No treatment-related deaths or neural complications were observed.
Dose escalation to 120 mg/m 2 of cisplatin per cycle was discussed among the members of the Head and Neck Cancer Study Group in the Japan Clinical Oncology Group. The proportion of patients administered 7 cycles of cisplatin (13/18) was a little more than two-thirds of the study population and the proportion of patients experiencing dose-limiting toxicities (5/18) was a little less than one-third. Therefore, dose escalation to 120 mg/m 2 of cisplatin per cycle was not performed and the recommended number of cycles was determined to be 7 cycles of 100 mg/m 2 cisplatin per cycle.
| DI S CU S S IO N
Robbins et al, 10 who originally developed RADPLAT, previously conducted a phase I study designed to determine the maximum-tolerated dose of cisplatin for intra-arterial administration. The number of cycles of cisplatin administered was fixed at 4 and the maximum-tolerated dose was set at 150 mg/m 2 once a week for the first 4 weeks. Next, they conducted a phase II study of a chemoradiation protocol based on intra-arterial cisplatin at 150 mg/m 2 every week for 4 doses with concomitant radiotherapy (1.8-2.0 Gy/day 3 35 fractions) for 29 patients with untreated stage IV head and neck cancer. 11 As mentioned above in the introduction, repeated cisplatin infusion while patients receive radiotherapy is, theoretically, more effective as it increases the radiosensitizing effect of cisplatin. Therefore, there was a concern that the radiosensitization was limited because cisplatin was concurrently administered with radiotherapy for only the first 4 of the 7 weeks of radiotherapy in the Robbins' regimen. We further considered the dose per cycle and the number of cycles of cisplatin. As for the dose per cycle, we adopted a dose of 100 mg/m 2 of cisplatin, which is commonly used in Japan. One institution in Japan treated 19 patients with maxillary sinus cancer by RADPLAT. 16 Patients were intended to receive 7 cycles at a dose of 100 mg/m 2 of cisplatin. Eventually, 13 patients (68%) received 7 cycles, 3 patients (16%) received 6 cycles, 2 patients (11%) received 5 cycles, and 1 patient (5%) received 4 cycles. With regard to adverse events grade 3, nausea/vomiting was observed in 7 patients and mucositis in 9 patients, which was considered to be acceptable. According to these results, 7 cycles at a dose of 100 mg/ m 2 of cisplatin seems to be feasible, and we did not consider a dose escalation study to be necessary. Rather, we planned to confirm the feasibility of 7 cycles at a dose of 100 mg/m 2 HOMMA ET AL.
of cisplatin in the multi-institutional setting. As for the number of cycles of cisplatin, we aimed at determining the recommended number of cycles in our study, which we speculated might be more than 4 cycles. Dose-limiting toxicities for this study was defined as any adverse event serious enough to prevent an increase in the number of cycles of cisplatin administered, such as grade 3 febrile neutropenia and grade 4 thrombocytopenia in terms of myelosuppression; estimated CCr < 40 mL/min, which is an important cisplatininduced toxicity; and complications related to intervention, which is a form of toxicity specific to this treatment. As a result, all patients were found able to receive a full dose of radiotherapy, and 13 patients received 7 cycles of intraarterial chemotherapy, with the remaining 5 patients receiving 6 cycles in the multi-institutional setting. doses with concomitant radiotherapy (70 Gy, 2 Gy/fraction, daily for 5 days over 7 weeks), although these trials did not include patients with sinonasal malignancies. In the former study, intra-arterial cisplatin infusions were delivered as follows: 4 infusions in 45 patients (74%); 3 infusions in 13 patients (21%); 1 infusions in 2 patients (3%); and 1 infusion in 1 patient (2%). Sixteen patients (26%) were administered < 600 mg/m 2 of cisplatin. In the latter trial, compliance, which was defined as complete delivery of both radiation and chemotherapy within the treatment time, was 76% (90/ 118). Compared with these results, a schedule consisting of 100 mg/m 2 of cisplatin per cycle is thought likely to result in better compliance. No treatment-related deaths or neural complications were observed in the dose-finding phase. As for grade 3/4 toxicities, both hematological toxicities (3 patients; 16.7%) and mucositis (4 patients; 22.2%) were observed. In RTOG 9515, grade 3/4 hematological toxicities and mucositis occurred in 51% and 58% of patients, respectively. However, RTOG 9515 was conducted in the 1990s and the radiation technique and supportive care used are considered to differ markedly from those in this study. 17 The development of antiemetic and comprehensive management for mucositis and dermatitis, including pain reduction therapy and nutritional support, is believed to have helped to reduce toxicities during and after treatment. Moreover, the radiation field in this study did not include the oral cavity or pharynx to any great extent. These factors are thought to have contributed to the lower incidence of severe adverse events and higher total dose of cisplatin administered. In addition, there were no catheter-related cerebrovascular accidents in the dose-finding phase, although the incidence of cerebrovascular accidents among patients treated by RADPLAT in other studies were variously reported to be 3.3% (grade 3), 19 6.8% (grade 2), 18 and 8.2% (grade 3). 17 This difference is thought to be due to the fact that patients with severe carotid stenosis, as evaluated by ultrasonography, were excluded from this study, and all interventional procedures were performed or directly supervised by interventional radiologists certified by the study chair. In addition, the training workshops held irregularly before and during the study period together with the semiannual investigator meetings may also have contributed to the absence of any catheter-related cerebrovascular accidents to date. These workshops not only contributed to safe performance of the treatment but also allowed more sophisticated interventional procedures to be performed in each institution.
The increase in the number of interventions resulted in an increase in the physicians' workload. However, it also resulted in more adept cisplatin infusion. For example, physicians sometimes found the ideal intra-arterial infusion to the targeted vessels in the first couple of interventions. Under such circumstances, the ideal intra-arterial chemotherapy can be achieved only once or twice in cases in which only 4 cycles are administered. On the other hand, the ideal intraarterial chemotherapy can be achieved more often if there are 7 cycles. We expect the increase in the number of interventions to lead to better tumor control.
The limitation of this study was that the treatment might not be applied to patients with lymph node metastasis, as patients with lymph node metastasis were excluded to ensure homogeneity of the population and allow more accurate evaluation of RADPLAT efficacy based on the fact that such patients were reported to have a poorer prognosis than those without lymph node metastasis. 12, 20 In addition, only 2 of the 18 patients enrolled in the dose-finding phase of this study were diagnosed with T4b disease. This might have been because normal tissue radiation dose constraints for the ipsilateral eyeball, optic nerve, and chiasma are not often satisfied by 3D-CRT in patients with T4b disease. Therefore, the protocol has been modified to use intensity-modulated radiotherapy instead of 3D-CRT in hospitals certified by the Japan Clinical Oncology Group Radiotherapy Committee. As a result, more patients with T4b disease are expected to be enrolled in the efficacy confirmation phase of this study.
In conclusion, RADPLAT seems to be safe and welltolerated at 7 cycles of cisplatin at a dose of 100 mg/m 2 per cycle, which was determined to be the recommended number of cycles for locally advanced maxillary sinus SCC. The efficacy confirmation phase was begun in January 2016 and is now open for accrual. A total of 65 patients with T4aN0M0 and 62 patients with T4bN0M0 will be enrolled in the efficacy confirmation phase.
